Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Heald

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Journal of Medicinal Chemistry|November 11, 2014
Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutationEmily J Hanan, Charles Eigenbrot, Marian C Bryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical ModelsGonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Science Advances|June 12, 2026
<i>SHLD2</i> loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapyGonzalo Rodriguez-Berriguete, Purusotha Thambiayah, Alessandro Cicconi, et al.
Journal of Medicinal Chemistry|January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Nucleic Acids Research|December 8, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapyEeson Rajendra, Claudio A Lademann, Bethany Mason, et al.
Journal of Medicinal Chemistry|December 8, 2025
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1Sam E Mann, Owen A Davis, Jörg Bomke, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor InhibitorBryan K Chan, Emily J Hanan, Krista K Bowman, et al.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Journal of Medicinal Chemistry|October 6, 2022
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase ThetaMartin L Stockley, Amanda Ferdinand, Giovanni Benedetti, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Journal of Medicinal Chemistry|November 11, 2014
Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutationEmily J Hanan, Charles Eigenbrot, Marian C Bryan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 23, 2023
Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical ModelsGonzalo Rodriguez-Berriguete, Marco Ranzani, Remko Prevo, et al.
Journal of Medicinal Chemistry|May 14, 2013
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activityChudi O Ndubaku, Timothy P Heffron, Steven T Staben, et al.
Science Advances|June 12, 2026
<i>SHLD2</i> loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapyGonzalo Rodriguez-Berriguete, Purusotha Thambiayah, Alessandro Cicconi, et al.
Journal of Medicinal Chemistry|January 8, 2016
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326)Timothy P Heffron, Robert A Heald, Chudi Ndubaku, et al.
Nucleic Acids Research|December 8, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapyEeson Rajendra, Claudio A Lademann, Bethany Mason, et al.
Journal of Medicinal Chemistry|December 8, 2025
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1Sam E Mann, Owen A Davis, Jörg Bomke, et al.
Journal of Medicinal Chemistry|August 27, 2016
Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor InhibitorBryan K Chan, Emily J Hanan, Krista K Bowman, et al.
Journal of Medicinal Chemistry|December 1, 2022
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3KαEmily J Hanan, Marie-Gabrielle Braun, Robert A Heald, et al.
Journal of Medicinal Chemistry|October 6, 2022
Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase ThetaMartin L Stockley, Amanda Ferdinand, Giovanni Benedetti, et al.
Pageof 11